JeanMarie Guenot is a pharmaceutical executive with over two decades of experience. Her expertise lies in project and alliance management, corporate and commercial development, and business development. Guenot specializes in rebuilding and building companies that record a slight decrease in their productivity.
As the current CEO and president of Amphivena Therapeutics, JeanMarie Guenot helps in developing antibody therapies targeting hematologic malignancies. Amphivena Therapeutics is a pharmaceutical company that has diverse flagship therapies for treating disorders such as malignancies. The institution was pleased to have Guenot join their leadership team.
Before Guenot joined Amphivena Therapeutics, she created SKS Ocular, an ophthalmic incubator. SKS Ocular focuses on developing dry AMD and drug technologies to treat ocular inflammation, glaucoma, and macular degeneration. Hoffmann-La Roche also appointed her as their business advisor. Guenot was also the VP of corporate and business development for PDL BioPharma. As the VP, she was in charge of alliance management of PDL’s product portfolios. She also handled licensing procedures as well as mergers and acquisitions.
One of the flagship products of PDL’s R&D was the Biogen Idec-PDL 50:50. Guenot advocated for the development and commercialization of this product. She also oversaw the clinical test that took three phases and involved autoimmune disease drug patients. Guenot was also present during the $800 M transaction that involved an equity investment split between Hoffmann-La Roche and Biogen Idec/PDL.
Guenot began her venture capital career as an investment manager for Atlas Venture. This position allowed her to manage and build life science companies and manage venture capital investments. Her professional scientific career began when she was hired as a principal scientist of Hoffmann-La Roche’s preclinical R&D. As the chief scientist, she developed and researched on drugs for treating oncology, autoimmune diseases, and metabolic diseases.
Guenot is versed in physical and medicinal chemistry. She attended the University of California for her Ph.D. As a Ph.D. student, she researched on semi-empirical and quantum mechanical methods for drug design, protein structure prediction, and molecular dynamics. Guenot also attended University of Pennsylvania’s The Wharton School for her MBA.